Genialis

Genialis, the RNA biomarker company, founded in 2015, aims to revolutionize healthcare outcomes. Leveraging the world’s most ethnographically diverse cancer datasets, the company develops clinically actionable biomarkers to predict patient responses and guide treatment decisions, including targeted inhibitors and immunotherapies. Genialis has garnered trust from pharma and diagnostics partners, positioning it as a key player in transforming medicine through data. In its latest milestone, Genialis secured a $13.00M Series A investment on 29 March 2023 from a consortium of notable investors including First Star Ventures, Redalpine, Debiopharm Innovation Fund, P5 Health Ventures, Taiwania Capital Management Corporation, and Pikas. With its innovative approach and strong investor backing, Genialis is poised to make significant strides in Biotechnology, Health Care, and Clean Energy.